These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


510 related items for PubMed ID: 17412298

  • 1. Human parvovirus B19 infection and antiphospholipid antibodies.
    von Landenberg P, Lehmann HW, Modrow S.
    Autoimmun Rev; 2007 Apr; 6(5):278-85. PubMed ID: 17412298
    [Abstract] [Full Text] [Related]

  • 2. Are antiphospholipid antibodies an essential requirement for an effective immune response to infections?
    von Landenberg P, Döring Y, Modrow S, Lackner KJ.
    Ann N Y Acad Sci; 2007 Jun; 1108():578-83. PubMed ID: 17894022
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Renal involvement of human parvovirus B19 in an immunocompetent host.
    Taylor G, Drachenberg C, Faris-Young S.
    Clin Infect Dis; 2001 Jan; 32(1):167-9. PubMed ID: 11106317
    [Abstract] [Full Text] [Related]

  • 5. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
    Von Landenberg P, Lehmann HW, Knöll A, Dorsch S, Modrow S.
    Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Infection with parvovirus B19: typical course of erythema infectiosum and its complications].
    Kirchesch H.
    Z Hautkr; 1990 Nov; 65(11):1007-10. PubMed ID: 1964320
    [Abstract] [Full Text] [Related]

  • 8. Parvovirus B19 infections.
    Sabella C, Goldfarb J.
    Am Fam Physician; 1999 Oct 01; 60(5):1455-60. PubMed ID: 10524489
    [Abstract] [Full Text] [Related]

  • 9. Parvovirus B19 infection and autoimmune disease.
    Lehmann HW, von Landenberg P, Modrow S.
    Autoimmun Rev; 2003 Jun 01; 2(4):218-23. PubMed ID: 12848949
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Parvovirus B19 infections. The cause of fifth disease-erythema infectiosum--can also cause aplastic crises, fetal damage and polyarthritis].
    Hornsleth A, Carlsen KM.
    Ugeskr Laeger; 1990 May 07; 152(19):1354-7. PubMed ID: 2160748
    [Abstract] [Full Text] [Related]

  • 12. Parvovirus B19: the causative agent of dilated cardiomyopathy or a harmless passenger of the human myocard?
    Modrow S.
    Ernst Schering Res Found Workshop; 2006 May 07; (55):63-82. PubMed ID: 16329658
    [Abstract] [Full Text] [Related]

  • 13. The seroprevalence of parvovirus B19 infection among to-be-married girls, pregnant women, and their neonates in Shiraz, Iran.
    Ziyaeyan M, Rasouli M, Alborzi A.
    Jpn J Infect Dis; 2005 Apr 07; 58(2):95-7. PubMed ID: 15858287
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Human parvovirus B19 infection in children: uncommon clinical presentations.
    Barash J, Dushnitzky D, Sthoeger D, Bardenstein R, Barak Y.
    Isr Med Assoc J; 2002 Oct 07; 4(10):763-5. PubMed ID: 12389336
    [Abstract] [Full Text] [Related]

  • 16. Aplastic crisis associated with parvovirus B19 in an adult with hereditary spherocytosis.
    Beland SS, Daniel GK, Menard JC, Miller NM.
    J Ark Med Soc; 1997 Sep 07; 94(4):163-4. PubMed ID: 9308316
    [Abstract] [Full Text] [Related]

  • 17. Human parvovirus B19 infection and autoimmunity.
    Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A.
    Autoimmun Rev; 2008 Dec 07; 8(2):116-20. PubMed ID: 18700174
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk of perinatal transmission of rubella and parvovirus B19 in Jordanian pregnant women.
    Bdour S.
    Vaccine; 2006 Apr 12; 24(16):3309-12. PubMed ID: 16460842
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 26.